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Abstract
Background: Conventional cancer therapy including surgery, radiation, and chemotherapy often
are physically debilitating and largely ineffective in previously treated patients with recurrent head
and neck squamous cell carcinoma (SCC). A natural photochemical, hypericin, could be a less
invasive method for laser photodynamic therapy (PDT) of these recurrent head and neck
malignancies. Hypericin has powerful photo-oxidizing ability, tumor localization properties, and
fluorescent imaging capabilities as well as minimal dark toxicity. The current study defined hypericin
PDT in vitro with human SCC cells before the cells were grown as tumor transplants in nude mice
and tested as a model for hypericin induced tumor fluorescence and PDT via laser fiberoptics.
Methods:  SNU squamous carcinoma cells were grown in tissue culture, detached from
monolayers with trypsin, and incubated with 0.1 μg to 10 μg/ml of hypericin before exposure to
laser light at 514, 550, or 593 nm to define optimal dose, time, and wavelength for PDT of tumor
cells. The SCC cells also were injected subcutaneously in nude mice and grown for 6–8 weeks to
form tumors before hypericin injection and insertion of fiberoptics from a KTP532 surgical laser to
assess the feasibility of this operating room instrument in stimulating fluorescence and PDT of
tumors.
Results: In vitro testing revealed a hypericin dose of 0.2–0.5 μg/ml was needed for PDT of the SCC
cells with an optimal tumoricidal response seen at the 593 nm light absorption maximum. In vivo
tumor retention of injected hypericin was seen for 7 to10 days using KTP532 laser induced
fluorescence and biweekly PDT via laser fiberoptics led to regression of SCC tumor transplants
under 0.4 cm2 diameter, but resulted in progression of larger size tumors in the nude mice.
Conclusion: In this preclinical study, hypericin was tested for 514–593 nm dye laser PDT of
human SCC cells in vitro and for KTP532 surgical laser targeting of SCC tumors in mice. The results
suggest hypericin is a potent tumor imaging agent using this surgical laser that may prove useful in
defining tumor margins and possibly in sterilizing post-resection margins. Deeply penetrating pulsed
infrared laser emissions will be needed for PDT of larger and more inaccessible tumors.
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Background
Current estimates indicate that 30,000 people will be
diagnosed with squamous cell carcinoma (SCC) of the
head and neck region each year in the USA and greater
than 8,000 of these patients will die of their disease.
Despite recent advances in surgical reconstruction permit-
ting larger resections in addition to new radiation and
chemotherapy regimes, the morbidity and mortality of
SCC has not decreased significantly in the last 20 years.
The median age of death remains 68 years of age and over
50% of head and neck SCC patients recur within 5 years
of treatment. For recurrent SCC, the five-year survival rate
is less than 10% [1]. Conventional cancer therapies
including surgery, radiation, and chemotherapy often are
physically debilitating and largely ineffective in previ-
ously treated recurrent head and neck tumors. Recent use
of laser thermal therapy to palliate these unresectable can-
cers has not proved effective in reducing the morbidity
and mortality of recurrent head and neck cancer patients.
The natural photosensitizing agent, hypericin, may pro-
vide a novel approach for less invasive treatment of locally
recurrent head and neck tumors [2-4]. Hypericin has pow-
erful photo-oxidizing ability, tumor-seeking characteris-
tics, and minimal dark toxicity, so it is potentially an ideal
therapeutic agent for treatment of recurrent SCC. Previous
preclinical studies have shown that use of hypericin in
photodynamic therapy (PDT) for cancer treatment is
effective and may prove to be a clinically valuable proce-
dure in targeting unresectable tumors via this minimally
invasive therapy [2-6]. Recently, we found hypericin PDT
of cultured human SCC cells in vitro can be activated by
visible laser light or infrared pulsed laser excitation [7]. In
the current study a low power variable wavelength dye
laser was used for hypericin-induced PDT of human SCC
cells in vitro and a KTP532 laser tested for effects on SCC
cells grown as tumors in mice.
Materials and methods
The human squamous carcinoma cell line SNU1 from
Seoul National University was grown in tissue culture.
SNU cells were cultured in RPMI 1640 medium supple-
mented with 10% fetal calf serum and 50 ug/ml gen-
tamicin as described previously [3]. Subconfluent
monolayers of the cells were detached with 0.25% trypsin
in PBS, counted in trypan blue with a hemocytometer,
and resuspended in microfuge tubes at 500,000 cells/0.5
ml in RPMI 1640 media without phenol red. These in vitro
experiments included hypericin concentrations ranging
from 0.1 to 10 μg/mL, dye laser wavelengths of 514, 550,
and 593 nm, laser power at the fiberoptic tip of 50, 100,
and 150 mW with illumination times of 0–120 seconds
for a total light fluence of 0–60 J/cm2 measured at the
sample tube liquid interface. After PDT each sample was
added to microplate wells at 50,000 cells/0.2 ml in tripli-
cate and incubated for 48 hours at 37°C before cell viabil-
ity was measured by adding 0.5 mg/ml MTT tetrazolium
bromide for 3 hours followed by media aspiration, addi-
tion of dimethyl sulfoxide (DMSO) to solubilize the dye
product, and optical density of each well recorded at 450
nm with a Molecular Devices microplate reader [3].
In vivo experiments were performed on 3–15 mm diame-
ter tumors growing in athymic nude mice 6–8 weeks after
subcutaneous injection of 106 human SCC cells. Tumors
were injected with 10 μL of DMSO containing 10 μg
hypericin per gm tumor and after 24 hours treated via
insertion of a fiberoptic into the tumor center to deliver
KTP 532 nm laser light at 500 mW output from a Laser-
scope operating room medical laser. KTP safety goggles
allowed detection of the orange-red dye tumor fluores-
cence. Hypericin spectra in DMSO had absorbance
maxima at 545 and 593 nm and a red-orange fluorescence
emission maxima at 594 and 640 nm as shown in Figure
1.
Results
This preclinical evaluation of hypericin was carried out to
assess its potential use as a new agent for sterilizing post-
operative resection margins in adjuvant treatment of
recurrent head and neck SCC where specific tumor target-
ing by photo-activation is needed to avoid normal tissue
damage to adjacent vital structures. Hypericin was tested
in the cultured SCC cells to define drug and light dosage
as well as light wavelength, exposure time, and laser
power delivery needed for tumoricidal effects. Both the in
vitro and in vivo experiments described in this study shows
that the photosensitizing effects of hypericin induced sig-
nificant killing of human SCC when excited by visible
light from a laser delivered via fiberoptics.
Hypericin singlet oxygen mediated phototoxicity in the
SCC cells was tested initially with the dye laser at a low
power of 50 mW using 3 wavelengths including green 514
nm, yellow 550 nm, and orange 593 nm light. As shown
in Figure 2, both 514 nm and 550 nm low intensity laser
light induced increased SCC cell death after prolonged
illumination, but 593 nm light was tumoricidal at expo-
sure times of 5–10 seconds with nearly complete cancer
cell killing after 120 seconds.
Drug phototoxicity in SCC cells then was tested at varying
hypericin concentrations and 593 nm laser light to assess
dose response. As shown in Figure 3, decreased SCC cell
viability was detectable even at the lowest hypericin dose
of 0.1 μg/mL and intense phototoxicity was observed at
0.2 μg/mL, compared to light exposed cells without drug.
At a constant light exposure time of 60 seconds and the
minimal 0.1 μg/mL drug level, cytotoxicity increased with
laser power delivery. These in vitro results show a dose-World Journal of Surgical Oncology 2006, 4:87 http://www.wjso.com/content/4/1/87
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response relationship exists in hypericin sensitized SCC
cells with elevated phototoxicity seen as either the drug or
light dosages were increased.
Next, photoactivation energy was varied after SCC cells
were sensitized with only 0.1 μg/mL hypericin and tumo-
ricidal responses to 593 nm light tested by increasing irra-
diation times and laser power delivery from 50 to 100 and
150 mW. The results in Figure 4 show significant tumor
cell killing at 150 mW after only 5–20 seconds light expo-
sure (0.75–3.0 Joules). The 50 mW and 100 mW laser
power level induced drug phototoxicity following longer
light exposure times.
After identifying optimal dosages for hypericin sensitiza-
tion and phototoxicity of SCC cells in vitro, hypericin was
then tested for uptake by the human SCC transplants
grown for 4–8 weeks as subcutaneous tumors in mice.
Hypericin injected into these subcutaneous tumors dif-
fused rapidly to the margins and remained for up to 10
days when monitored by laser-induced fluorescence as
shown below in Figure 5. Insertion of a bare fiberoptic
allowed delivery of KTP532 laser green light into the
tumor site inducing intense red-orange fluorescence of
hypericin when viewed with KTP532 safety goggles.
Enhanced hypericin fluorescence also was observed in the
tumor by inserting a cylindrical fiberoptic tip redirecting
the 532 nm laser photons at right angles from the fiber
axis as shown in Figure 6. These results confirmed that
hypericin dye diffuses into and is retained by these SCC
tumors for prolonged periods. The commonly available
KTP532 medical laser also was highly effective in exciting
Visible light absorbance and fluorescence spectrum of hypericin in DMSO Figure 1
Visible light absorbance and fluorescence spectrum of hypericin in DMSO.World Journal of Surgical Oncology 2006, 4:87 http://www.wjso.com/content/4/1/87
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hypericin fluorescence and appears likely to be useful in
defining tumor margins during resection of head and neck
cancer in the operating room.
Direct  in vivo laser PDT also was tested on mice after
weekly intratumor injection of hypericin. Of 30 SCC
tumors evaluated by repeated PDT over 6–8 weeks via
KTP532 laser fiberoptic insertion, we observed gradual
tumor ablation in half of the treated mice. Use of the
fiberoptic diffuser tip in phototherapy of several SCC
tumors was not an improvement. In one case an open
tumor was injected with hypericin and illuminated
biweekly via a bare fiber from above leading to a complete
response as shown in Fig 6, 7, 8, 9, 10. Hypericin and laser
photo-oxidation proved to be most effective in tumors of
smaller size with a volume of 400 mm3 or less, while
larger tumors often exhibited partial ablation followed by
regrowth. The results show 532 nm light penetration was
a limiting factor in PDT of larger tumors and suggest
hypericin may be most effective in defining tumor mar-
gins by laser induced fluorescence and sterilizing the post-
resection field.
Discussion
Initial treatment of head and neck squamous cell carci-
noma is directed by several considerations with the single
most important factor being stage of disease [1]. However,
with the advent of newer chemoradiation protocols, an
increase in the number of recurrent squamous cell carci-
nomas has been seen. These recurrent patients usually
have no surgical options and need newer modalities of
treatment in hopes of palliation after receiving maximum
dose radiation or appearance of drug resistant tumors [1].
Tumor imaging and PDT with hypericin have been tested
in vivo for therapy of pancreas and skin cancer as well as in
nasopharyngeal carcinomas [5,8,11]. Experimental stud-
ies have shown that hypericin photodynamic therapy is
tumoricidal for human cancer cells both in vitro and in vivo
with potential application in targeting recurrent or unre-
sectable malignancies through this minimally invasive
new adjuvant procedure [2-7].
The current study supports previously reported data and
provides new evidence that hypericin may prove to be
clinically useful for both tumor imaging and in PDT of
locally recurrent head and neck squamous cell carcinoma.
As seen in Figs 5 and 6, hypericin is effective as a fluores-
cent tumor imaging agent when activated by a conven-
tional operating room KTP532 surgical laser. In an earlier
study, we reported that intravenous hypericin injection
resulted in significant uptake by SCC tumors, but higher
levels of this fluorescent dye were deposited in the lungs
and other vascular organs [2]. Although 532 nm laser light
was sufficient for hypericin excitation and in fluorescent
Hypericin phototoxicity in SCC cells at 3 dye laser light emission wavelengths Figure 2
Hypericin phototoxicity in SCC cells at 3 dye laser light emission wavelengths.
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tumor imaging, the in vitro SCC experiments of the current
study show clearly that the higher 593 nm laser wave-
length is superior in phototherapy. This conclusion also
was indicated by a decreased PDT response observed for
large SCC tumors after hypericin and KTP532 laser treat-
ment even when fiberoptics were inserted directly into the
tumor center to maximize the light delivery. Recent
reports show hypericin phototherapy can be enhanced by
multi-fraction treatment, by the addition of synthetic oxy-
gen carriers, or by co-administration of a cyclo-oxygenase
inhibitor to block prostaglandin synthesis and prevent
new angiogenesis in tumor sites [9-11]. Further improve-
ment of hypericin PDT also may be possible using 2-pho-
ton infrared pulsed laser emissions to increase tissue
penetration of light during tumor imaging and treatment
[7]. These advances will make hypericin and lasers a more
effective cancer therapy.
Conclusion
The photodynamic response of hypericin dye was tested in
vitro with cultured human squamous carcinoma cells after
exposure to laser emissions at green, yellow, and orange
visible light wavelengths (514, 550, and 593 nm). This
study revealed that the greatest PDT responses occurred at
hypericin's absorption and fluorescence maximum of 593
nm. A range of hypericin concentrations was tested to
determine the minimum dosage for photosensitization of
the tumor cells, which was found to be from 0.2 to 0.5 μg/
mL or 1 μM. Laser power delivery at 150 mW produced
the highest level of tumor cell killing at 593 nm. In vivo
studies with nude mice bearing human squamous cell car-
cinoma tumors showed that injected hypericin remained
within the tumor site for 10 days allowing repeated laser
illumination.
This study also confirms that placement of the fiberoptic
within the tumor provides the greatest photo-oxidation
and is the optimal route of laser light delivery. During
these PDT tests of subcutaneous human SCC tumors
using a surgical KTP532 laser emitting visible green light,
the limiting factor appears to be tumor size. Hypericin
PDT also should be enhanced via deeper penetration of
593 nm light as in our in vitro studies above or by using
longer wavelengths of pulsed infrared light for 2-photon
excitation [7]. This study provides new evidence hypericin
is an ideal photosensitizer for PDT that may prove to be
Hypericin dose and laser light fluence effects on SCC cell phototoxicity Figure 3
Hypericin dose and laser light fluence effects on SCC cell phototoxicity.
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Hypericin in SCC tumor of nude mouse viewed by laser-induced fluorescence Figure 5
Hypericin in SCC tumor of nude mouse viewed by laser-induced fluorescence.
Hypericin PDT of SCC cells at increasing exposure times and laser power Figure 4
Hypericin PDT of SCC cells at increasing exposure times and laser power.
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Open SCC tumor in nude mouse prior to hypericin and KTP laser treatment Figure 7
Open SCC tumor in nude mouse prior to hypericin and KTP laser treatment.
Hypericin intratumor fluorescence induced by laser fiberoptic cylindrical tip Figure 6
Hypericin intratumor fluorescence induced by laser fiberoptic cylindrical tip.World Journal of Surgical Oncology 2006, 4:87 http://www.wjso.com/content/4/1/87
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Tumor viewed via KTP532 safety goggles during hypericin and laser phototherapy Figure 8
Tumor viewed via KTP532 safety goggles during hypericin and laser phototherapy.
Tumor two months after semi-weekly cycles of hypericin and KTP laser PDT Figure 9
Tumor two months after semi-weekly cycles of hypericin and KTP laser PDT.World Journal of Surgical Oncology 2006, 4:87 http://www.wjso.com/content/4/1/87
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clinically useful in tumor imaging and minimally invasive
treatment of locally recurrent head and neck squamous
cell carcinoma.
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